A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and
tolerability study in adults with ADHD. The target subjects are healthy male or female adults
aged 18 to 64 years, inclusive, with a diagnosis of ADHD. A total of fifty subjects will be
enrolled at approximately 5 sites in the US. Subjects will be randomized (1:1) to one of two
treatment groups, SPN-812V or placebo.